NRG-BR009: A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)

Objective

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).

National Clinical Trial (NCT) Number: 05879926

National Library of Medicine clinicaltrials.gov Website Address: https://clinicaltrials.gov/study/NCT05879926

Location: Essentia Health Cancer Centers

Research Study Categories

• Adult Oncology Studies

Specialties

• Breast Cancer

Contact

Cancer Clinical Trials at 218-786-3308 or 844-681-7944, [email protected]